Glucocorticosteroids, such as deflazacort or prednisone, are the current standard of care treatment for DMD patients (Araujo 2023).84Genetic therapies that act by regulating the expression ofDMDor administering a transcript capable of encoding a smaller but still functional dystrophin have been the most promising therapies. This evidence concerns the gene DMD and Duchenne muscular dystrophy.